The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
Crit Rev Oncol Hematol
; 143: 20-26, 2019 Nov.
Article
em En
| MEDLINE
| ID: mdl-31449983
ABSTRACT
Approximately 30-50% of advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer patients will develop brain metastases (BMs) during the disease course. Brain metastases may become a main limitation of life expectancy and a half of them will die from brain progression. Even in patients with early HER2-positive breast cancer managed with curative therapy, the risk of brain metastases is also increased. Central nervous system (CNS) may usually present as the first site of recurrence in HER2-positive breast cancer. Local treatments including radiotherapy and surgery are essential while new chemotherapy and biological agents appear to contribute a significant role in the future treatment field of CNS metastases. This article will review recent progresses in HER2-positive breast cancer with BM, with a focus on the efficacy of the HER2 targeted agents-trastuzumab emtansine (T-DM1).
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Neoplasias da Mama
/
Receptor ErbB-2
/
Ado-Trastuzumab Emtansina
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article